Literature DB >> 19399844

Vascular endothelial growth factor gene transfer for diabetic polyneuropathy.

John A Kessler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19399844      PMCID： PMC3724533          DOI： 10.1002/ana.21686

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  26 in total

1.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Can VEGF reverse diabetic neuropathy in human subjects?

Authors:  A Veves; G L King
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.

Authors:  A Wellmer; V P Misra; M K Sharief; P G Kopelman; P Anand
Journal:  J Peripher Nerv Syst       Date:  2001-12       Impact factor: 3.494

Review 4.  Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.

Authors:  N E Cameron; S E Eaton; M A Cotter; S Tesfaye
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

5.  Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.

Authors:  S C Apfel; S Schwartz; B T Adornato; R Freeman; V Biton; M Rendell; A Vinik; M Giuliani; J C Stevens; R Barbano; P J Dyck
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

6.  Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor.

Authors:  M Sondell; F Sundler; M Kanje
Journal:  Eur J Neurosci       Date:  2000-12       Impact factor: 3.386

7.  Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA.

Authors:  Saul Benedict Freedman; Peter Vale; Christoph Kalka; Marianne Kearney; Anne Pieczek; James Symes; Douglas Losordo; Jeffrey M Isner
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

8.  Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial.

Authors:  Allan H Ropper; Kenneth C Gorson; Clifton L Gooch; David H Weinberg; Ann Pieczek; James H Ware; Joshua Kershen; Adam Rogers; Drasko Simovic; Peter Schratzberger; Rudolf Kirchmair; Douglas Losordo
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

9.  Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy.

Authors:  Robert E Schmidt; Denise A Dorsey; Lucie N Beaudet; Richard G Peterson
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 10.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?

Authors:  Stuart C Apfel
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230
View more
  2 in total

Review 1.  Identifying Common Genetic Risk Factors of Diabetic Neuropathies.

Authors:  Ini-Isabée Witzel; Herbert F Jelinek; Kinda Khalaf; Sungmun Lee; Ahsan H Khandoker; Habiba Alsafar
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-28       Impact factor: 5.555

2.  Development of sensory neuropathy in streptozotocin-induced diabetic mice.

Authors:  Tatsufumi Murakami; Takayuki Iwanaga; Yoshinao Ogawa; Yoshiaki Fujita; Eiji Sato; Hironori Yoshitomi; Yoshihide Sunada; Akihiro Nakamura
Journal:  Brain Behav       Date:  2012-12-23       Impact factor: 2.708
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.